Cargando…

The Antitumor Activity of CAR-T-PD1 Cells Enhanced by HPV16mE7-Pulsed and SOCS1-Silenced DCs in Cervical Cancer Models

BACKGROUND: Genetically T cells modified with cancer-specific chimeric antigen receptors (CARs) showed great promise in mediate tumor regression, especially in patients with advanced leukemia. However, the therapeutic effect against solid tumors is not as prominent as anticipated to exhibit potent a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Jingwei, Huang, Jingsong, Ma, Wei, Yang, Wenqiang, Hu, Bicheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349543/ https://www.ncbi.nlm.nih.gov/pubmed/34377023 http://dx.doi.org/10.2147/CMAR.S321402

Ejemplares similares

SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression
por: Berzaghi, R., et al.
Publicado: (2017)

Erratum: SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression
por: Berzaghi, R., et al.
Publicado: (2017)

Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed/refractory acute myeloid leukemia
por: Lin, Guoqiang, et al.
Publicado: (2021)

Endoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects
por: Xie, Shenxia, et al.
Publicado: (2021)

Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
por: Wang, Yu-meng, et al.
Publicado: (2022)

SOCS3 Silencing Attenuates Eosinophil Functions in Asthma Patients
por: Zafra, Mª Paz, et al.
Publicado: (2015)

Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy
por: Chen, Xianhui, et al.
Publicado: (2021)

PD-1/PD-L1 expression on CD(4+) T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation
por: Liu, Li, et al.
Publicado: (2015)

Effects of valproic acid on SOCS-1, SOCS-2, SOCS-3, SOCS-5, SOCS6, and SOCS-7 gene expression and cell growth inhibition in colon carcinoma
por: Sanaei, Masumeh, et al.
Publicado: (2022)

SOCS1 as a Biomarker Candidate for HPV Infection and Prognosis of Head and Neck Squamous Cell Carcinomas
por: Guo, Manli, et al.
Publicado: (2023)

Silencing SOCS1 via Liposome-Packed siRNA Sustains TLR4-Ligand Adjuvant
por: Hildebrand, Dagmar, et al.
Publicado: (2019)

Methylation profiling of SOCS1, SOCS2, SOCS3, CISH and SHP1 in Philadelphia-negative myeloproliferative neoplasm
por: Zhang, Min Yue, et al.
Publicado: (2013)

Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers
por: Ba, Hongping, et al.
Publicado: (2023)

Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
por: Serganova, Inna, et al.
Publicado: (2016)

CD1d highly expressed on DCs reduces lung tumor burden by enhancing antitumor immunity
por: Li, Yifan, et al.
Publicado: (2019)

The Immunotherapeutic Effect of SIRPα-Silenced DCs against Cervical Cancer
por: Li, Xiaojie, et al.
Publicado: (2020)

Correlation of PD-L1 and SOCS3 Co-expression with the Prognosis of Hepatocellular Carcinoma Patients
por: Chen, Liuxi, et al.
Publicado: (2020)

Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3
por: Ventero, Maria Paz, et al.
Publicado: (2019)

Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1
por: an, Zhijing, et al.
Publicado: (2021)

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
por: John, Liza B, et al.
Publicado: (2013)

Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity
por: Shi, Xiaojuan, et al.
Publicado: (2019)

Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses
por: Bu, Xia, et al.
Publicado: (2021)

Prostaglandin E(2) and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment
por: Miao, Jie, et al.
Publicado: (2017)

TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy
por: Nai, Yaru, et al.
Publicado: (2021)

Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma
por: Vandenberk, Lien, et al.
Publicado: (2015)

Expression of PD-L1 is HPV/P16-independent in oral squamous cell carcinoma
por: Kitichotkul, Kit, et al.
Publicado: (2022)

The AIDA DCS1 System
por: Kersten, Susanne, et al.
Publicado: (2014)

Correction: Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3
por: Ventero, Maria Paz, et al.
Publicado: (2019)

Silenced suppressor of cytokine signaling 1 (SOCS1) enhances the maturation and antifungal immunity of dendritic cells in response to Candida albicans in vitro
por: Shi, Dongmei, et al.
Publicado: (2014)

Silencing of STIM1 attenuates hypoxia-induced PASMCs proliferation via inhibition of the SOC/Ca(2+)/NFAT pathway
por: Hou, Xianhua, et al.
Publicado: (2013)

Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
por: Wang, Zhengyi, et al.
Publicado: (2020)

Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
por: Thuru, Xavier, et al.
Publicado: (2022)

Bispecific GPC3/PD-1 CAR-T cells for the treatment of HCC
por: Li, Dezhi, et al.
Publicado: (2023)

Rapid Inflammation in Mice Lacking Both SOCS1 and SOCS3 in Hematopoietic Cells
por: Ushiki, Takashi, et al.
Publicado: (2016)

Function of PD-L1 in antitumor immunity of glioma cells
por: Lou, Yongli, et al.
Publicado: (2017)

Screening and identification of an anti-PD-1 nanobody with antitumor activity
por: Zhang, Yanting, et al.
Publicado: (2023)

PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity
por: Wiede, Florian, et al.
Publicado: (2022)

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
por: Rodriguez-Marquez, Paula, et al.
Publicado: (2022)

Current status of the clinical use of PD-1/PD-L1 inhibitors: a questionnaire survey of oncologists in China
por: Zhang, Bicheng, et al.
Publicado: (2020)

PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice
por: Hu, Zhengping, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_36i4smcvnc2a0i9r0qfssitk7p